# Global Managed Access Program Cohort for Remibrutinib in Adult Patients With Chronic Spontaneous Urticaria

> **NCT05170724** · — · AVAILABLE · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Chronic Spontaneous Urticaria

## Interventions

- **DRUG:** Remibrutinib

## Key facts

- **NCT ID:** NCT05170724
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05170724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05170724, "Global Managed Access Program Cohort for Remibrutinib in Adult Patients With Chronic Spontaneous Urticaria". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05170724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*